Galectin Therapeutics Inc

Research Galectin Therapeutics Inc (GALT) on Bullrun: market cap USD 327.31M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerGALT
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 327.31M
• Financial periodFY2025
• Net income-USD 30.84M

Valuation Snapshot

latest market cap is USD 327.31M.

About Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc.

Frequently asked questions

What is Galectin Therapeutics Inc's market cap?

Galectin Therapeutics Inc's market capitalization is USD 327.31M.

What does Galectin Therapeutics Inc do?

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer.